Royalty Pharma plc [NASDAQ: RPRX] closed the trading session at $37.14 on 02/23/23. The day’s price range saw the stock hit a low of $36.98, while the highest price level was $37.375. The company report on February 15, 2023 that Royalty Pharma Reports Q4 and Full Year 2022 Results.
Net cash provided by operating activities (GAAP) of $570 million and Adjusted Cash Receipts(1) (non-GAAP) of $1,064 million in Q4 2022.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Sponsored
Announced transactions of up to $3.5 billion in 2022, including $2.0 billion in upfront payments.
The stocks have a year to date performance of -6.02 percent and weekly performance of -1.46 percent. The stock has been moved at -14.52 percent over the last six months. The stock has performed -2.93 percent around the most recent 30 days and changed -13.47 percent over the most recent 3-months.
If compared to the average trading volume of 1.53M shares, RPRX reached to a volume of 3495963 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Royalty Pharma plc [RPRX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for RPRX shares is $53.16 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on RPRX stock is a recommendation set at 1.90. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
UBS have made an estimate for Royalty Pharma plc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on June 14, 2022. While these analysts kept the previous recommendation, Scotiabank raised their target price to Sector Outperform. The new note on the price target was released on May 13, 2022, representing the official price target for Royalty Pharma plc stock. Previously, the target price had yet another raise to $56, while Goldman analysts kept a Buy rating on RPRX stock.
The Average True Range (ATR) for Royalty Pharma plc is set at 0.68, with the Price to Sales ratio for RPRX stock in the period of the last 12 months amounting to 9.92. The Price to Book ratio for the last quarter was 2.92, with the Price to Cash per share for the same quarter was set at 4.06. Price to Free Cash Flow for RPRX in the course of the last twelve months was 321.19 with Quick ratio for the last quarter at 2.20.
RPRX stock trade performance evaluation
Royalty Pharma plc [RPRX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.46. With this latest performance, RPRX shares dropped by -2.93% in over the last four-week period, additionally sinking by -14.52% over the last 6 months – not to mention a drop of -3.63% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for RPRX stock in for the last two-week period is set at 34.89, with the RSI for the last a single of trading hit 32.88, and the three-weeks RSI is set at 36.39 for Royalty Pharma plc [RPRX]. The present Moving Average for the last 50 days of trading for this stock 38.92, while it was recorded at 37.33 for the last single week of trading, and 41.19 for the last 200 days.
Royalty Pharma plc [RPRX]: An insightful look at the core fundamentals
Royalty Pharma plc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.20 and a Current Ratio set at 2.20.
Earnings per share (EPS) analysis for Royalty Pharma plc [RPRX] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for RPRX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Royalty Pharma plc go to 10.55%.
Royalty Pharma plc [RPRX]: Insider Ownership positions
There are presently around $11,047 million, or 68.40% of RPRX stock, in the hands of institutional investors. The top three institutional holders of RPRX stocks are: MORGAN STANLEY with ownership of 49,246,032, which is approximately -1.873% of the company’s market cap and around 0.10% of the total institutional ownership; FMR LLC, holding 44,110,365 shares of the stock with an approximate value of $1.64 billion in RPRX stocks shares; and VANGUARD GROUP INC, currently with $1.32 billion in RPRX stock with ownership of nearly 1.934% of the company’s market capitalization.
198 institutional holders increased their position in Royalty Pharma plc [NASDAQ:RPRX] by around 16,608,597 shares. Additionally, 134 investors decreased positions by around 15,017,379 shares, while 39 investors held positions by with 265,803,052 shares. The mentioned changes placed institutional holdings at 297,429,028 shares, according to the latest SEC report filing. RPRX stock had 63 new institutional investments in for a total of 4,436,391 shares, while 34 institutional investors sold positions of 2,589,191 shares during the same period.